Public health and valorization of genome-based technologies: a new model

<p>Abstract</p> <p>Background</p> <p>The success rate of timely translation of genome-based technologies to commercially feasible products/services with applicability in health care systems is significantly low. We identified both industry and scientists neglect health policy aspects when commercializing their technology, more specifically, Public Health Assessment Tools (PHAT) and early on involvement of decision makers through which market authorization and reimbursements are dependent. While Technology Transfer (TT) aims to facilitate translation of ideas into products, Health Technology Assessment, one component of PHAT, for example, facilitates translation of products/processes into healthcare services and eventually comes up with recommendations for decision makers. We aim to propose a new model of valorization to optimize integration of genome-based technologies into the healthcare system.</p> <p>Methods</p> <p>The method used to develop our model is an adapted version of the Fish Trap Model and the Basic Design Cycle.</p> <p>Results</p> <p>We found although different, similarities exist between TT and PHAT. Realizing the potential of being mutually beneficial justified our proposal of their relative parallel initiation. We observed that the Public Health Genomics Wheel should be included in this relative parallel activity to ensure all societal/policy aspects are dealt with preemptively by both stakeholders. On further analysis, we found out this whole process is dependent on the Value of Information. As a result, we present our LAL (Learning Adapting Leveling) model which proposes, based on market demand; TT and PHAT by consultation/bi-lateral communication should advocate for relevant technologies. This can be achieved by public-private partnerships (PPPs). These widely defined PPPs create the innovation network which is a developing, consultative/collaborative-networking platform between TT and PHAT. This network has iterations and requires learning, assimilating and using knowledge developed and is called absorption capacity. We hypothesize that the higher absorption capacity, higher success possibility. Our model however does not address the phasing out of technology although we believe the same model can be used to simultaneously phase out a technology.</p> <p>Conclusions</p> <p>This model proposes to facilitate optimization/decrease the timeframe of integration in healthcare. It also helps industry and researchers to come to a strategic decision at an early stage, about technology being developed thus, saving on resources, hence minimizing failures.</p

In Vitro and In Vivo Antagonism of a G Protein-Coupled Receptor (S1P3) with a Novel Blocking Monoclonal Antibody

Background: S1P 3 is a lipid-activated G protein-couple receptor (GPCR) that has been implicated in the pathological processes of a number of diseases, including sepsis and cancer. Currently, there are no available high-affinity, subtypeselective drug compounds that can block activation of S1P3. We have developed a monoclonal antibody (7H9) that specifically recognizes S1P3 and acts as a functional antagonist. Methodology/Principal Findings: Specific binding of 7H9 was demonstrated by immunocytochemistry using cells that over-express individual members of the S1P receptor family. We show, in vitro, that 7H9 can inhibit the activation of S1P3mediated cellular processes, including arrestin translocation, receptor internalization, adenylate cyclase inhibiton, and calcium mobilization. We also demonstrate that 7H9 blocks activation of S1P3 in vivo, 1) by preventing lethality due to systemic inflammation, and 2) by altering the progression of breast tumor xenografts. Conclusions/Significance: We have developed the first-reported monoclonal antibody that selectively recognizes a lipidactivated GPCR and blocks functional activity. In addition to serving as a lead drug compound for the treatment of sepsi

CONTENT CURATION FOR INFORMATION LITERACY AND KNOWLEDGE MANAGEMENT IN IMMUNOLOGY USING SCOOP.IT

International audienceReferences The topics, curated almost daily, gather more than 25K highly selected scoops over the last 40 months, compared to 200K or 400K results found with Pubmed or Google Scholar respectively on similar topics. Scoops are dealing with published (classical or OPEN) and grey literature (blogs, websites, social networks, press releases…) allowing rapid access to recently published relevant information. The audience is steadily increasing, with over 175K views, and more than 70K visitors for the most successful topic entitled Immunology (http://www.scoop.it/t/immunology), covering basic immunology (5,8K scoops, >101 K views) since 2011. Immunological basic sciences, Biotechnologies, BioTherapies are covered by the following topics besides Immunology: From Flow Cytometry to Cytomics, http://www.scoop.it/t/from-flow-cytometry-to-cytomics (3,9K scoops, >18,5 K views) Immunology and Biotherapies, http://www.scoop.it/t/immunology-and-biotherapies (5,7K scoops, >14K views) Mucosal Immunity http://www.scoop.it/t/mucosal-immunity (2,9K s, 7.5K v) History of Immunology. http://www.scoop.it/t/history-of-immunology Immuno-Pathology is covered through topics: Autoimmunity, http://www.scoop.it/t/autoimmunity (2,5K s, 6K v) Allergy (and clinical immunology), http://www.scoop.it/t/allergy-and-clinical-immunology Rheumatology